 LEXINGTON, Mass.--BUSINESS WIRE--Aldeyra Therapeutics, Inc. Nasdaq: ALDX Aldeyra, a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases, today announced the pricing of an underwritten public offering of 6,842,106 shares of its common stock at a public offering price of 9.50 per share. The gross proceeds from the offering, before deducting underwriting discounts and commissions 